Publications

363 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period
Period

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:
  1. GVS advice SGLT-2 inhibitors

    The National Health Care Institute has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin ...

    Report | 22-06-2021

  2. GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia

    Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...

    Report | 14-06-2021

  3. GVS advice onosilodrostat (Isturisa®) for the treatment of endogenous Cushing syndrome

    The National Health Care Institute advises the Minister to include osilodrostat on List 1A in cluster 0V04CDAO V. Osilodrostat ...

    Report | 14-06-2021

  4. GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia

    The National Health Care Institute has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a ...

    Report | 08-06-2021

  5. GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection

    The National Health Care Institute has completed its assessment whether the products Rekambys® and Vocabria® can be included in ...

    Report | 08-06-2021

  6. Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma

    The National Health Care Institute has completed its assessment whether isatuximab (Sarclisa®) in combination with carfilzomib ...

    Report | 25-05-2021

  7. GVS advice ivacaftor (Kalydeco®) extension of further conditions

    Zorginstituut Nederland carried out a review to extend the further conditions for reimbursement of ivacaftor (Kalydeco®). The ...

    Report | 25-05-2021

  8. GVS advice dapagliflozin (Forxiga®) extension of further condition

    The National Health Care Institute has completed its assessment whether the further condition of dapagliflozin (Forxiga®) could ...

    Report | 12-05-2021

  9. Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer

    Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...

    Report | 11-05-2021

  10. Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA

    Zorginstituut Nederland has completed its assessment whether onasemnogene abeparvovec (Zolgensma®) for the treatment of patients ...

    Report | 06-05-2021